Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01414738 : Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases
PhasePhase 2
AgesMin: 18 Years Max: 99 Years
Inclusion Criteria:

1. Pathologically (histologically or cytologically) proven diagnosis of a
non-hematopoietic malignancy other than small cell lung cancer and germ cell
malignancy.. Direct biopsy of CNS lesions is not necessarily required although could
constitute an allowed site of tissue confirmation as medically prudent. Patients who
have been disease free for more than 5 years prior to the appearance of CNS
metastases should undergo repeat biopsy of either a systemic metastasis or the CNS
metastases to confirm the recurrent malignancy.

2. Patients with measurable brain metastasis outside a 5-mm margin around either

3. Patients with measurable brain metastasis who have not been or will not be treated
with SRS or surgical resection (Note: These treatment options are only permitted at

4. History/physical examination within 28 days prior to registration

5. Patients must fall into RTOG recursive partitioning analysis (RPA) class I or II

6. Patients must have a life expectancy of at least 4 months.

7. Age ? 18 years

8. Karnofsky performance status ? 70

9. Patients must provide study-specific informed consent prior to study entry

10. Women of childbearing potential and male participants must practice adequate

11. Women of childbearing potential must have a negative, qualitative serum pregnancy
test ?2 weeks prior to study entry

Exclusion Criteria:

1. Patients with greater than 9 discrete metastases on MRI.

2. Patients with leptomeningeal metastases

3. Patients with measurable brain metastasis not resulting from small cell lung cancer
and germ cell malignancy

4. Plan for chemotherapy or targeted therapies during WBRT or over the subsequent 7 days

5. Contraindication to MR imaging such as implanted metal devices or foreign bodies,
severe claustrophobia AND patients unable to receive gadolinium contrast agents

6. Serum creatinine > 1.4 mg/dl ? 28 days prior to study entry

7. Prior radiation therapy to the brain

8. Patients planning to undergo radiosurgery to any CNS lesion OR patients planning to
have surgical resection of ALL of their CNS lesions
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557